More than 500 million people are persistently infected with hepatitis B
virus (HBV) and/or hepatitis C virus (HCV) and are
at a risk of developing chronic hepatitis,
cirrhosis, and liver cancer. The absence of robust cell culture systems
for both
viral infections limits the understanding
of the virus lifecycle and pathogenesis required for the development of
vaccine
and antivirals. We have established a
novel human hepatoma cell line termed “HLCZ01” that supports the entire
lifecycle of
both HBV and HCV produced both in cell
culture and clinically. This cell line provides a powerful tool for
addressing the
virus lifecycle and the development of
antivirals and vaccines.
Read more... Labels: Research and Discoveries, viral replication